日本語
 
Help Privacy Policy ポリシー/免責事項
  詳細検索ブラウズ

アイテム詳細

登録内容を編集ファイル形式で保存
 
 
ダウンロード電子メール
  Gastric Adenocarcinomas Express the Glycosphingolipid Gb(3)/CD77: Targeting of Gastric Cancer Cells with Shiga Toxin B-Subunit

Geyer, P. E., Maak, M., Nitsche, U., Perl, M., Novotny, A., Slotta-Huspenina, J., Dransart, E., Holtorf, A., Johannes, L., & Janssen, K.-P. (2016). Gastric Adenocarcinomas Express the Glycosphingolipid Gb(3)/CD77: Targeting of Gastric Cancer Cells with Shiga Toxin B-Subunit. Molecular Cancer Therapeutics, 15(5), 1008-1017. doi:10.1158/1535-7163.MCT-15-0633.

Item is

基本情報

表示: 非表示:
資料種別: 学術論文

ファイル

表示: ファイル

関連URL

表示:

作成者

表示:
非表示:
 作成者:
Geyer, Philipp Emanuel1, 著者           
Maak, Matthias2, 著者
Nitsche, Ulrich2, 著者
Perl, Markus2, 著者
Novotny, Alexander2, 著者
Slotta-Huspenina, Julia2, 著者
Dransart, Estelle2, 著者
Holtorf, Anne2, 著者
Johannes, Ludger2, 著者
Janssen, Klaus-Peter2, 著者
所属:
1Mann, Matthias / Proteomics and Signal Transduction, Max Planck Institute of Biochemistry, Max Planck Society, ou_1565159              
2external, ou_persistent22              

内容説明

表示:
非表示:
キーワード: HUMAN BREAST-CANCER; HEMOLYTIC-UREMIC SYNDROME; COLON-CANCER; STEM-CELLS; TUMOR; RECEPTOR; BINDING; VEROTOXIN; DELIVERY; PROTEINOncology;
 要旨: The B-subunit of the bacterial Shiga toxin (STxB), which is nontoxic and has low immunogenicity, can be used for tumor targeting of breast, colon, and pancreatic cancer. Here, we tested whether human gastric cancers, which are among the most aggressive tumor entities, express the cellular receptor of Shiga toxin, the glycosphingolipid globotriaosylceramide (Gb(3)/CD77). The majority of cases showed an extensive staining for Gb(3) (36/50 cases, 72%), as evidenced on tissue sections of surgically resected specimen. Gb(3) expression was detected independent of type (diffuse/intestinal), and was negatively correlated to increasing tumor-node-metastasis stages (P = 0.0385), as well as with markers for senescence. Gb(3) expression in nondiseased gastric mucosa was restricted to chief and parietal cells at the bottom of the gastric glands, and was not elevated in endoscopic samples of gastritis (n = 10). Gb(3) expression in established cell lines of gastric carcinoma was heterogeneous, with 6 of 10 lines being positive, evidenced by flow cytometry. STxB was taken up rapidly by live Gb(3)-positive gastric cancer cells, following the intracellular retrograde transport route, avoiding lysosomes and rapidly reaching the Golgi apparatus and the endoplasmic reticulum. Treatment of the Gb(3)-expressing gastric carcinoma cell line St3051 with STxB coupled to SN38, the active metabolite of the topoisomerase type I inhibitor irinotecan, resulted in >100-fold increased cytotoxicity, as compared with irinotecan alone. No cytotoxicity was observed on gastric cancer cell lines lacking Gb(3) expression, demonstrating receptor specificity of the STxB-SN38 compound. Thus, STxB is a highly specific transport vehicle for cytotoxic agents in gastric carcinoma. (C) 2016 AACR.

資料詳細

表示:
非表示:
言語: eng - English
 日付: 2016
 出版の状態: 出版
 ページ: 10
 出版情報: -
 目次: -
 査読: 査読あり
 識別子(DOI, ISBNなど): ISI: 000375857400022
DOI: 10.1158/1535-7163.MCT-15-0633
 学位: -

関連イベント

表示:

訴訟

表示:

Project information

表示:

出版物 1

表示:
非表示:
出版物名: Molecular Cancer Therapeutics
  その他 : Mol. Cancer Ther.
種別: 学術雑誌
 著者・編者:
所属:
出版社, 出版地: Philadelphia, PA : American Association for Cancer Research, Inc.
ページ: - 巻号: 15 (5) 通巻号: - 開始・終了ページ: 1008 - 1017 識別子(ISBN, ISSN, DOIなど): ISSN: 1535-7163
CoNE: https://pure.mpg.de/cone/journals/resource/111022849554084